RhumbLine Advisers
GSK icon

RhumbLine Advisers’s GSK GSK Stock Holding History

RhumbLine Advisers’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$805K Buy
15,359
+196
+1% +$10.4K ﹤0.01% 2456
2026
Q1 		$837K Sell
15,163
-445
-3% -$24.1K ﹤0.01% 2292
2025
Q4 		$765K Sell
15,608
-6,725
-30% -$314K ﹤0.01% 2380
2025
Q3 		$964K Buy
22,333
+124
+0.6% +$4.84K ﹤0.01% 2266
2025
Q2 		$853K Buy
22,209
+3,806
+21% +$145K ﹤0.01% 2322
2025
Q1 		$713K Buy
18,403
+386
+2% +$14.1K ﹤0.01% 2344
2024
Q4 		$609K Sell
18,017
-70
-0.4% -$2.52K ﹤0.01% 2541
2024
Q3 		$739K Buy
18,087
+1,425
+9% +$58.3K ﹤0.01% 2434
2024
Q2 		$641K Buy
16,662
+151
+0.9% +$6.35K ﹤0.01% 2492
2024
Q1 		$708K Buy
16,511
+3,721
+29% +$153K ﹤0.01% 2445
2023
Q4 		$474K Buy
12,790
+1,690
+15% +$60.7K ﹤0.01% 2685
2023
Q3 		$402K Buy
11,100
+555
+5% +$19.7K ﹤0.01% 2739
2023
Q2 		$376K Buy
+10,545
New +$378K ﹤0.01% 2875
2016
Q3 		– Sell
-21,480
Closed -$1.16M – 2902
2016
Q2 		$1.16M Hold
21,480
– – ﹤0.01% 1690
2016
Q1 		$1.09M Buy
21,480
+240
+1% +$12K ﹤0.01% 1735
2015
Q4 		$1.07M Buy
21,240
+1,040
+5% +$53K ﹤0.01% 1759
2015
Q3 		$971K Hold
20,200
– – ﹤0.01% 1783
2015
Q2 		$1.05M Sell
20,200
-5,520
-21% -$311K ﹤0.01% 1829
2015
Q1 		$1.48M Sell
25,720
-1,840
-7% -$105K ﹤0.01% 1604
2014
Q4 		$1.47M Hold
27,560
– – ﹤0.01% 1545
2014
Q3 		$1.58M Sell
27,560
-1,040
-4% -$63.8K ﹤0.01% 1481
2014
Q2 		$1.91M Buy
28,600
+1,120
+4% +$75.8K 0.01% 1403
2014
Q1 		$1.83M Sell
27,480
-160
-0.6% -$10.8K 0.01% 1402
2013
Q4 		$1.84M Buy
27,640
+8,240
+42% +$534K 0.01% 1421
2013
Q3 		$1.22M Buy
19,400
+10,320
+114% +$664K ﹤0.01% 1649
2013
Q2 		$567K Buy
+9,080
New +$576K ﹤0.01% 2164

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

RhumbLine Advisers's GSK Position: Q2 2026 in Review

RhumbLine Advisers increased its GSK (GSK) stake by 1.3% in Q2 2026, buying an estimated $10.4K and bringing the position to 15,359 shares worth $805K. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

RhumbLine Advisers first reported a position in GSK in Q2 2013 and has held it in 26 quarters since. The position peaked at $1.91M in Q2 2014. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • RhumbLine Advisers held 15,359 shares of GSK worth $805K as of Q2 2026.
  • RhumbLine Advisers bought 196 GSK shares in Q2 2026, an estimated $10.4K.
  • GSK made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2456 holding.
  • RhumbLine Advisers first reported a position in GSK in Q2 2013 and has held it in 26 quarters since.
  • RhumbLine Advisers's GSK position peaked at $1.91M in Q2 2014.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.